Important: Formulation and dosage details
Formulation:
Tablets 5mg, 10mg
Dosage:
5mg daily, increased if necessary after 3 to 4 weeks to 10mg once daily.
We are pleased to advise that deep linking capability, enabling users to directly download individual mobile toolkits, has now been released on the RDS mobile app. When you install the update, you will see that each toolkit has a small QR code icon the header area beside the search icon – see screenshot below. Clicking on this icon will open up a window with a full-size QR code and the alternative of a short URL for sharing with users. Instructions are provided.
You may need to actively install the update to install RDS app version 4.7.1 to see this improvement. Installing this update is also strongly recommended to get the full benefits of the new contingency arrangements – specifically, that if the RDS website should fail, you will still be able to download new mobile app toolkits.
To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. To install latest updates:
On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.
On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.
Please get in touch with ann.wales3@nhs.scot with any questions.
Patients’ response to drugs within this class is idiosyncratic. It may be necessary to try different drugs before a response occurs. Mirabegron is the first beta-3 adrenoceptor agonist to treat symptoms of overactive bladder and offers an alternative where anticholinergics are either not tolerated or are ineffective.
For guidance on the management of urinary incontinence in women refer to www.nice.org.uk.
For local continence care guidance and continence products see the North Highland Community Catheter and Appliances Formulary.
MHRA advice: Mirabegron (Betmiga) risk of severe hypertension and associated cerebrovascular and cardiac events (October 2015) (www.gov.uk).
Modified release tablets 25mg, 50mg
50mg once daily.
For dosing in patients with renal or hepatic impairment in the absence or presence of strong cytochrome P450 inhibitors such as itraconazole, ketoconazole, ritonavir, or clarithromycin, refer to SPC.
Tablets 2·5mg, 5mg
Initially 2·5 to 5mg 2 to 3 times daily increased if necessary to maximum 5mg 4 times daily
Modified release tablets 5mg, 10mg
Modified release: 5mg daily, adjusted according to response in 5mg steps at weekly intervals, maximum 20mg daily taken as a single dose.